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Abstract
Post-exposure vaccination with vaccinia virus (VACV) has been suggested to be effective in minimizing death if
administered within four days of smallpox exposure. While there is anecdotal evidence for efficacy of post-exposure
vaccination this has not been definitively studied in humans. In this study, we analyzed post-exposure prophylaxis
using several attenuated recombinant VACV in a mouse model. A recombinant VACV expressing murine interferon
gamma (IFN-γ) was most effective for post-exposure protection of mice infected with VACV and ectromelia virus
(ECTV). Untreated animals infected with VACV exhibited severe weight loss and morbidity leading to 100% mortality
by 8 to 10 days post-infection. Animals treated one day post-infection had milder symptoms, decreased weight loss
and morbidity, and 100% survival. Treatment on days 2 or 3 post-infection resulted in 40% and 20% survival,
respectively. Similar results were seen in ECTV-infected mice. Despite the differences in survival rates in the VACV
model, the viral load was similar in both treated and untreated mice while treated mice displayed a high level of IFN-γ
in the serum. These results suggest that protection provided by IFN-γ expressed by VACV may be mediated by its
immunoregulatory activities rather than its antiviral effects. These results highlight the importance of IFN-γ as a
modulator of the immune response for post-exposure prophylaxis and could be used potentially as another post-
exposure prophylaxis tool to prevent morbidity following infection with smallpox and other orthopoxviruses.
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Introduction
Vaccinia virus (VACV) is a member of the genus
Orthopoxvirus of the family Poxviridae. Other members of this
family include variola virus (VARV), the causative agent of
smallpox; monkeypox virus (MPXV), ectromelia virus (ECTV),
camelpox virus (CMLV) and cowpox virus (CPXV) [1][2]. After
an intensive vaccination strategy using VACV, which was
initiated in 1967, smallpox was declared eradicated from the
world in 1980 and routine smallpox vaccination was
discontinued in the USA in 1972 [3][4]. This leaves the majority
of the current world population susceptible to severe disease
from certain orthopoxvirus infections. After September 11,
2001, there was heightened concern for the use of VARV or
MPXV as a bioterrorism agent and the low, but real, risk of an
accidental VARV release [5][6][7]. For these reasons it was
important to develop a post-exposure prophylaxis strategy.
There are diverse antiviral agents that have been considered
as alternative strategies for post-exposure treatment of
smallpox. One of the antiviral drugs that has been shown to be
effective against different poxviruses is (S)-1-(3-hydroxy-2-
phosphonylmethoxypropyl)-cytosine also known as HPMPC,
Vistide, and more commonly as cidofovir [8][9]. While cidofovir
has been shown to protect monkeypox-infected macaques
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when administered 24 hours post-infection (hpi), its potential is
limited by nephrotoxicity and the lack of oral availability [9].
Likewise, vaccine immune globulin (VIG), has also been
suggested to be used as prophylaxis in patients for whom
smallpox vaccine is contraindicated [10].
Antivirals ST-246 and CMX001 have shown promise as
antipoxviral drugs and are in phase I and II clinical trials [11]
[12][13][14][15][16]. ST-246 protects ground squirrels against
monkeypox challenge when administered up to 3 days post-
exposure [17]. Treatment with VIGIV (Vaccinia Immune
Globulin Intravenous) and cidofovir along with ST-246 (multiple
doses) was successful in the treatment of a 28-month-old child
with severe eczema vaccinatum [18][19]. Similarly, a
combination therapy using VIGIV, ST-246, Imiquimod and
CMX001, a lipid conjugate of cidofovir, were used to treat
progressive vaccinia in a military vaccinee [20]. Moreover,
VIGIV and ST-246 have recently been used to treat human
vaccinia virus infection in a 35 year-old woman after contact
with raccoon rabies bait [21]. Although it is difficult to assess
the contribution of each agent because of the close timing of
administration, these cases are an example of the utility of new
treatments.
Post-exposure vaccination with VACV has also been
suggested to be an effective treatment if administered within
four days of smallpox exposure [22]. While there is anecdotal
evidence for efficacy of post-exposure vaccination this has not
been definitively studied in humans. Therefore, various animal
models have been used to study the efficacy of post-exposure
treatment with various VACV strains following poxvirus
infection. While infection of humans with smallpox has a 14 day
period from initial infection to the prodrome phase, the various
animal models show pathology via weight loss within 3-4 days
following infection. Therefore the time during which post-
exposure prophylaxis can occur is abbreviated in these
models.
A recent model of post-exposure immunization with modified
VACV Ankara (MVA) and the VACV-Lister strain proved to be
effective in an ECTV infection model when post-exposure
vaccination was performed at 1, 2 and 3 days post-infection
(dpi). Protection was shown to be dependant on the vaccine
dose as well as the day of vaccination [23]. A second model
employs the Western Reserve (WR) strain of VACV as a
challenge virus in mice. Therapeutic vaccination with MVA was
minimally protective only at 1 dpi while the Elstree (Lister)
strain failed to provide any detectable protection [24].
Because cytokines are highly regulated during VACV
infection, they have been thoroughly studied in this context [25]
[26][27][28]. While IL-2, TNF-α and IFN-γ decrease virulence
during a VACV infection, others such as IL-4 have been shown
to increase virulence and pathogenicity [25][26][27][28].
Another cytokine, IL-18, which can induce endogenous
synthesis of IFN-γ, has been shown to promote clearance of
VACV infection when expressed together with IL-12, indicating
the synergistic action of both cytokines[29].
The present work employed recombinant VACV for post-
exposure prophylaxis in an animal model. We evaluated
several recombinant VACVs as therapeutic vaccines including
1) viruses containing mutations within the VACV E3L gene, an
IFN resistance gene [30][31] and 2) viruses expressing murine
IFN-γ (muIFN-γ) [32] or murine IL-18 (muIL-18) from the VACV
B13R locus. In this study we demonstrate that post-exposure
prophylaxis with a recombinant VACV expressing IFN-γ is
100% effective in protecting mice infected with 100 LD50s of wt
VACV as well as 83.3% effective in protecting mice infected
with 55 LD50s of ECTV when administered 1 dpi.
Materials and Methods
Ethics statement
Animal experiments performed at Arizona State University
were approved and carried out under the IACUC protocol
number 08-970R. Animal husbandry and experimental
procedures performed at Saint Louis University were in
accordance with Public Health Service policy, and approved by
Animal Care and Use Committee. The IACUC protocol number
1339 was followed for these studies.
Viruses and cells
VACV.  The WR strain of VACV was used as the parental
virus for these studies. The E3L VACV mutants were
generated by standard methods routinely employed in our
laboratory. Construction of VACV mutants expressing E3LΔ7C
and E3LΔ26C has previously been described [33].
VACVΔE3L::ATVeIF2α has a replacement of the E3L gene
with the eukaryotic initiation factor 2 alpha (eIF2α) homologue
from the Ambystoma tigrinum virus, genus Ranavirus, family
Iridoviridae [34]. The recombinant VACV expressing IFN-γ
(v50ΔB13RMγ) virus was constructed as previously described
[32]. This virus expresses the vesicular stomatitis virus
glycoprotein (VSV-G) at the TK locus and lacZ, gpt, and
muIFN-γ at the B13R site, thus both VACV genes are
inactivated. The recombinant VACV expressing IL-18
(v50ΔB13RMIL‑18) is essentially the same as v50ΔB13RMγ,
but expresses the muIL-18 gene instead of muIFN-γ. The
muIL‑18 gene was cloned from mouse spleen cDNA
(unpublished data). Construction of the parental virus
(v50ΔB13R) has already been described [35]. Viruses were
amplified in Baby Hamster Kidney 21 (BHK) cells and partially
purified by pelleting through a 36% sucrose pad, as previously
described [36][37]. BHK and Rabbit Kidney 13 (RK) cells were
cultured in minimal essential medium (MEM, Gibco, BRL)
containing 5% fetal bovine serum (FBS), 50 μg/ml of
gentamycin, 0.1 mM nonessential amino acid solution (Gibco,
BRL), and vitamin supplements. Cells were incubated at 37°C
with 5% CO2.
ECTV.  African green monkey kidney epithelial cells (BSC-1,
ATCC CCL-26) were grown in Eagle’s MEM containing 10%
fetal clone III serum (Hyclone, Logan, UT), 2mM L-glutamine
(GIBCO, Grand Island, NY), 100 U/ml penicillin (GIBCO, Grand
Island, NY), and 100 μg/ml streptomycin (GIBCO, Grand
Island, NY). A plaque-purified isolate of the MOS strain of
ECTV (ATCC VR-1374) designated MOS-3-P2 was
propagated in BSC-1 cells [38]. Virus was partially purified
through a sucrose cushion [39], and infectivity was estimated,
as described previously [40]. Briefly, virus suspensions were
serially diluted in phosphate buffered saline (PBS) + 1% FBS,
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absorbed to monolayers for 1 h at 37°C, and overlaid with a
suspension of 1% carboxymethyl cellulose in DMEM+ 5% fetal
clone III serum. After 4 days at 37°C, plaques were visualized
by staining with a 0.3% crystal violet/10% formalin solution.
Mice and in vivo infections
VACV infections.  Four-week old female C57BL/6 mice
were obtained from Charles River and maintained at the
Arizona State University Department of Animal Care and
Technologies. Each cage contained a maximum of 5 mice and
a separate cage was used for each experimental condition.
Treatment groups consisted of 5 to 15 mice. An anesthetic
cocktail containing xylazine (7.5 mg/ml), acepromazine maleate
(2.5 mg/ml), and ketamine (37.5 mg/ml) was prepared.
Approximately 1 μl of cocktail was injected intramuscularly per
gram of body weight [31]. Following anesthesia, one naris was
infected with a 5 μl dose of 106 pfu (~100 LD50s) of wt VACV.
Mice were treated 1, 2 or 3 dpi with 102 - 107 pfu of treatment
virus administered intranasally (IN) into the same or opposite
naris as the challenge virus in a 5 ml volume. Scarification
infection of mice was done as previously described [41]. IM
injections were performed by injecting 5 ml of virus suspension
into the left leg using a 26-gauge needle. Disease symptoms
and animals’ health were monitored every other day for the
length of the experiment.
ECTV infections.  Eight to ten-week-old male or female
C57BL/6 mice were obtained from the National Cancer
Institute, (Frederick, MD), housed in filtertop microisolator
cages and fed commercial mouse chow and water, ad libitum.
The mice were housed in an animal biosafety level 3
containment area. One day prior to challenge with ECTV,
individual mice were weighed and assigned to treatment
groups of 10 to 20 mice. On the day of challenge, mice were
anesthetized with 0.1 ml/10 g body weight of ketamine HCl (9
mg/ml) and xylazine (1 mg/ml) by intraperitoneal injections.
Anesthetized mice were laid on their dorsal side with their
bodies angled so that the anterior end was raised 45° from the
surface. A plastic mouse holder was used to ensure conformity.
ECTV was diluted in PBS to the required dose (5 x 103 pfu) and
slowly loaded into each naris (5 μl/naris). Mice were
subsequently left in situ for 2–3 min before being returned to
their cages. One day following challenge, groups of mice were
treated by the foot pad (FP) route with 3 x 107 pfu of
v50ΔB13RMγ or v50ΔB13R. Mice were weighed every 2 days
and observed for morbidity and mortality.
Weight loss
Weight loss was determined by weighing each mouse on
alternate days. The percent weight gain or loss was determined
and animals that lost more than 30% of their original body
weight were euthanized by an IP injection of anesthesia or by
CO2 inhalation and considered dead from the challenge. A
relative sickness index that takes into consideration typical
symptoms of a wt VACV infection was created. Each animal
from each group was assigned an arbitrary score (1-4) based
on the severity of the following symptoms: ruffled fur, lack of
activity, breathing difficulty, eye infection, hunching and weight
loss. This index also takes into consideration the number of
animals euthanized within each group (each death accounts for
a value of 0.8 in the death/life score, if all animals in the group
die, the line stops).
Tissue distribution
Animals were infected IN with 106 pfu of wt VACV (Day 0)
and treated with 107 pfu of v50ΔB13RMγ. On alternate days
beginning with 2 dpi, three animals were euthanized and then
immediately dissected. The organs removed (nasal cavity,
brain, lungs, heart, liver, spleen, kidney and ovaries) were
immediately frozen in liquid nitrogen and then stored at -80°C.
A 10% homogenate was prepared for each organ by adding 1
mM Tris pH 8.8 with gentamycin. All tissues with the exception
of the nasal cavity were then homogenized using a PCR tissue
homogenizing kit (Fisher). The nasal cavity was homogenized
using a Mixer Miller 301 device (Retsch). All homogenates
were subjected to three rounds of freezing (−80°C), slow
thawing for 30 min on ice and then quick thawing (37°C). After
three rounds of freezing-thawing, samples were subjected to a
7 minute spin using a tabletop centrifuge at 700 x g at 4°C to
remove all cell debris. After centrifugation, supernatants were
retained and dilutions were performed for plaque assays on
RK13 cells.
Viral loads for tissue distribution were conducted in triplicate
by infecting monolayers of RK cells. Forty-eight hours post-
infection, two replicates were stained with crystal violet to
determine the viral load within the tissue (pfu per g of tissue).
Differentiation of wt VACV and the treatment v50ΔB13RMγ
virus was done by overlaying the third replica with 1% agarose,
MEM 5% FBS and 400 μg/ml X-Gal (5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside). The v50ΔB13RMγ could be
identified due to the fact that this virus expresses lacZ from the
B13R locus.
ELISA
Animals were infected on day 0, treated on day 1, and 24
hours later blood was collected from the superficial temporal
vein into BD serum separator tubes. Serum was collected after
centrifugation following manufacturer’s recommendations and
stored at -80°C. An ELISA to detect murine IFN-γ was
performed using a kit from Thermo Fisher. Briefly, plates
precoated with IFN-γ antibody were incubated with serum
samples diluted 1:2 in standard diluent, washed, and incubated
with a second biotin-conjugated IFN-γ antibody. After washing,
streptavidin-HRP was added, and detection was performed
using TMB substrate solution. The reaction was stopped with
dilute sulfuric acid and a plate reader was used to measure the
absorbance at 450nm.
Immunohistochemistry
Tissues were perfused with phosphate-buffered saline (PBS)
via cardiac injection followed by fixation with 10% formalin.
After the soft tissue was removed the skull was decalcified
using ethylene glycol tetraacetic acid (EGTA). The skull was
embedded in paraffin and sliced at a 3 μm thickness using a
microtome starting at the tip of the nasal cavity and moving in
an anterior direction. Deparaffinized tissue sections of the
nasal cavity were incubated with 2% H2O2 in methanol for 10
Post-Exposure Prophylaxis for Poxvirus Infections
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minutes to quench endogenous peroxidases and then rinsed in
PBS. Detection of VACV antigen was done using rabbit anti-
VACV and the VECTASTAIN Elite ABC kit (Rabbit IgG) from
VECTOR Laboratories. Color development was performed
using the 3,3'-diaminobenzidine (DAB) Substrate Kit from
VECTOR Laboratories following the manufacturer's protocol.
Data analysis
Survival analysis was done using Kaplan-Meier curves and
the log-rank test and Mann-Whitney analyses were performed
using the statistical software program GraphPad Prism (version
5.0c for Macintosh).
Results
v50ΔB13RMγ causes weight recovery and protects
mice from death
The WR strain of VACV was originally derived from serial
passages in mouse brain and thus is a neurotropic, highly
virulent strain of VACV [42]. Several VACV WR mutants of E3L
(an IFN antagonist protein) as well as VACV WR recombinants
expressing either muIL-18 or muIFN-γ were tested for their
ability to confer protective post-exposure prophylaxis in mice
upon challenge with a lethal dose of VACV WR. The VACV
E3L mutants chosen for this study have previously been shown
to have reduced pathogenesis and neurovirulence phenotypes
in mice [31]. Similarly, IL-18 was selected due to its pro-
inflammatory properties, ability to induce synthesis of IFN-γ,
activation of NK cells and its main role in the T-lymphocyte
helper type 1 response [43]. IFN-γ was chosen due to its
multiple immune stimulatory effects on macrophage activities,
NK cell cytolysis, and T and B cell responses [26][44][45][46]
[47].
IN infections of C57BL/6 mice were performed with ~100
LD50s wt VACV as described in the materials and methods
section. Animals were then treated 1 dpi with 107 pfu of the
mutant or recombinant viruses. As shown in Figure 1A, all
animals lost weight to day 6 post-infection, but only mice
treated with v50ΔB13RMγ recovered. Figure 1B shows the
survival rate for each of the mutants tested. Treatment with
v50ΔB13RMIL-18 resulted in 60% survival (P<0.005, log-rank
test) while 30% survival was observed when animals were
treated with either VACVΔE3L, VACVE3LΔ7C or
VACVE3L::ATVeIF2α (P>0.05, log-rank test) and 20% survival
when treated with VACVE3LΔ26C (P<0.05, log-rank test). Only
treatment with v50ΔB13RMγ was able to confer 100% survival
(P<0.0001, log-rank test). Partial protection was seen with
doses as low as 105 pfu, while full protection required treatment
with 107 pfu (Figure 1C).
The parental virus of v50ΔB13RMγ, v50ΔB13R, was also
evaluated in order to assess if the protection from mortality was
a result of the expression of IFN-γ or whether it was a result of
the parental virus containing a deletion of the serpin gene
B13R. This gene is nonessential for VACV replication, however
deletion from the virus results in reduced replication and
pathogenesis in mice [35]. Treatment of mice infected with wt
VACV as described above with the parental virus (v50ΔB13R)
was analyzed. This virus did not provide protection against
infection with VACV with only 17% surviving (data not shown,
P>0.5, log-rank test), suggesting that expression of IFN-γ and
not the deletion of B13R, is responsible for the survival of the
mice.
Post-Exposure Prophylaxis with v50ΔB13RMγ Is More
Effective When Administered One Day Post-Infection
In order to determine the temporal requirements of
protection, animals were infected with 106 pfu (~100 LD50s) of
wt VACV and then treated with 107 pfu of v50ΔB13RMγ at 1, 2,
or 3 dpi. Animals showed 100% survival when treated 1 dpi,
while all mock-treated animals died by day 8 (P<0.005, log-
rank test). Protection was reduced to 40% (P<0.05, log-rank
test) when treatment virus was administered at 2 dpi, and to
20% (P>0.05, log-rank test) when animals were treated at 3 dpi
(Figure 2A). Additionally, when animals were initially infected
with ten-fold more wt VACV (107 pfu or 1000 LD50s) followed by
treatment 1 dpi with v50ΔB13RMγ a slight decrease to 80%
survival was observed (P<0.005, log-rank test).
A relative sickness index with values from 0 to 4 was created
as indicated in the materials and methods section. Animals
given 1 x 106 pfu of wt VACV without therapeutic vaccination
reached a relative sickness index of 2.7 by 6 dpi and
succumbed to the infection by 8 dpi. However, mice that were
treated with 107 pfu v50ΔB13RMγ at 1 dpi reached a maximum
relative sickness of 0.9 by 6 dpi. By day 18, these mice
attained weights that were comparable to the mock-infected
mice (data not shown) and had a relative sickness index of 0.
Interestingly, animals that were treated either 2 or 3 dpi
showed similar morbidity and had a sickness index similar to
that of the untreated animals at 8 dpi, (2.5 versus 2.7).
However, when animals were infected with 107 pfu of wt VACV
and treated 1 dpi, they reached a maximum score of 1.1 by 8
dpi and the animals that survived showed a slightly delayed
recovery as compared to mice infected with 106 pfu wt VACV
and treated 1 dpi (Figure 2B).
The intranasal route of administration of post-exposure
prophylaxis with v50ΔB13RMγ is most effective
In the previous experiments, all viruses were administered
into the same naris of the animal. Since the current smallpox
vaccine is given by scarification and several vaccines are
administered by intramuscular (IM) injection, animals were
challenged IN as described above and treated with
v50ΔB13RMγ into the same naris (IN), opposite naris (INON),
by scarification (SCA) or by IM injection. The results show that
100% protection occurred only when the treatment was given
into the same naris as the challenge virus (P<0.0001, log-rank
test) (Figure 3). On the other hand, mice that remained
untreated had marked weight loss, morbidity and died 8 dpi.
INON treatment resulted in 40% survival (P<0.005, log-rank
test), and IM or SCA treatment resulted in 20% and 15%
survival, respectively (P>0.5, log-rank test) (Figure 3). As in
previous experiments, a relative sickness index was generated.
Animals that were treated within the same naris had the lowest
relative sickness index, 0.6 at 8 dpi, while treatment in the
opposite naris had an index of 1.74 and treatment via SCA or
Post-Exposure Prophylaxis for Poxvirus Infections
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Figure 1.  Post-exposure protection of animals after intranasal infection with a lethal dose of wt VACV and subsequent
treatment with different VACV mutants.  (A) Weight loss. Groups of 5 to 10 four-week-old C57BL/6 mice were infected
intranasally with 106 pfu (~100 LD50s) of wt VACV and treated 1 dpi with 107 pfu of VACVE3LΔ7C (○), VACVE3LΔ26C (●),
VACVΔE3L (♦), VACVΔE3L::ATVeIF2α (□), v50ΔB13RMγ (▲) and v50ΔB13RMIL-18 (∆). There were two groups of control animals,
one group was infected with wt VACV alone and was mock-treated (■), the second group of animals was mock-infected and mock-
treated (◊). Each mouse was weighed at the indicated times. Average percentage of initial weight of the animals infected with each
virus is plotted versus time (days post-infection). Lines end at the death of one animal. Error bars indicate the standard error of the
mean. (B) Survival curve. The data represent a pool of two independent experiments using group sizes of 5 mice. (C) v50ΔB13RMγ
dose response. Groups of 10 four-week-old C57BL/6 mice were infected intranasally with 106 pfu of wt VACV (~100 LD50s) and
treated one day post-infection with doses of 102, 103, 104, 105, 106, 107 and 5 x 108 pfu of v50ΔB13RMγ (▲).
doi: 10.1371/journal.pone.0077879.g001
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Figure 2.  Protection of wt VACV infected animals by post-exposure vaccination with v50ΔB13RMγ at one, two and three
days post-infection.  Groups of 5 to 10 C57BL/6 mice were infected intranasally with 106 pfu (~100 LD50s) of wt VACV. Animals
were treated with 107 pfu of v50ΔB13RMγ at one (▲), two (●) or three (♦) days post-infection. One group was infected with 107 pfu
(~1000 LD50s) of wt VACV and treated with 107 pfu of v50ΔB13RMγ at one day post-infection (∆). Controls animals were infected
with wt VACV and then mock-treated (■), or animals were mock-infected and mock-treated (◊). (A) Comparison of survival curves
was done using the log-rank test. (B) Recovery of wt VACV infected animals by post-exposure vaccination with v50ΔB13RMγ at
one, two and three days post-infection. The graph indicates the relative sickness of each group of animals during the course of the
infection. Lines ending prematurely indicate death of all the animals from the group. A value of 0 indicates that all the animals from
that group were healthy.
doi: 10.1371/journal.pone.0077879.g002
Post-Exposure Prophylaxis for Poxvirus Infections
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IM injection had the highest sickness index of 2.0 by 8 dpi,
similar to untreated animals (data not shown).
Viral spread of wt VACV was similar in untreated and
treated animals
IFN-γ is both an effective antiviral as well as a modulator of
the immune response by leading to the activation of
macrophages and neutrophils and to increased expression of
MHC class I and II proteins [26][44] which could limit the
spread of VACV and lead to protection. To determine the
kinetics of replication and viral spread, various mouse tissues
(nasal cavity, brain, lungs, heart, liver, spleen, kidney and
ovaries) were examined. At 2 dpi wt VACV was observed in the
nasal cavity, brain, lungs and spleen of mock-treated animals
(Figure 4A). Animals that were treated with v50ΔB13RMγ
showed similar viral loads in the nasal cavity, brain and spleen
as in untreated animals, but no virus was detected in the lungs
at 2 dpi (Figure 4B). By 4 dpi wt VACV was detected in all of
the organs examined with similar titers in most tissues in both
untreated and treated animals (Figures 4A and 4B). However,
at 4 dpi titers in the brain of treated animals were two logs
lower than titers in the brain of untreated mice while titers in the
ovaries of treated mice were two logs higher than in untreated
mice. At 6 dpi, titers in the ovaries of treated and untreated
mice were similar. By 6 dpi, viral loads in treated animals
peaked within the nasal cavity, brain, heart, and lungs and
reached titers close to those observed in untreated animals at
4 dpi. By 10 dpi VACV could only be detected in the nasal
cavity, brain, and lungs indicating that the treated animals were
effectively clearing the viral load (Figure 4B). X-gal staining
was done in order to differentiate v50ΔB13RMγ from wild-type
virus. Examination of the different tissues revealed a low level
of replication of this virus in the nasal cavity (4-8 dpi) and brain
(2 and 6 dpi), as well as detection in the heart and lungs of
animals, one at 6 dpi and one at 8 dpi respectively (Figure 4C).
Animals treated with v50ΔB13RMγ show increased
levels of IFN-γ in the serum
Serum was collected 24 hours following mock treatment or
treatment with v50ΔB13R or v50ΔB13RMγ, and an ELISA was
performed to measure IFN-γ. Mock-infected, mock-treated
animals had the lowest levels of IFN-γ at 38 pg/ml, whereas
Figure 3.  Post-exposure protection of wt VACV infected animals treated with v50ΔB13RMγ using different routes of
treatment.  Groups of 12 to 15 C57BL/6 mice were infected intranasally with 106 pfu of wt VACV. Animals were treated one day
post-infection with 107 pfu of v50ΔB13RMγ intranasally, IN (▲), intranasally using the other nostril, INON (∆), intramuscularly, IM (○)
or via scarification, SCA (●). One group of animals was infected with wt VACV and then mock-treated (■), another group was mock-
infected and mock-treated (◊). Comparison of survival curves was done using the log-rank test.
doi: 10.1371/journal.pone.0077879.g003
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Figure 4.  Viral spread of wt VACV in infected animals.  Groups of 3 C57BL/6 mice were infected intranasally with 106 pfu of wt
VACV. Animals remained untreated (A) or were treated one day post-infection with 107 pfu of v50ΔB13RMγ (B). Replication of
v50ΔB13RMγ in the tissues from the treated group was examined by X-gal staining (C). Error bars indicate the standard error of the
mean. Data represent a pool of two independent experiments using 3 mice per group.
doi: 10.1371/journal.pone.0077879.g004
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treating these mice with v50ΔB13RMγ resulted in an increase
to 362 pg/ml IFN-γ (Figure 5). Animals that were wt-infected,
mock-treated showed slightly elevated IFN-γ at 120 pg/ml.
When wt-infected animals were treated with the parental virus,
v50ΔB13R, 296 pg/ml IFN-γ was observed, whereas animals
that were treated with v50ΔB13RMγ showed the highest levels
of IFN-γ with an average of 1156 pg/ml (Figure 5). The wt-
infected, v50ΔB13RMγ-treated animals showed statistically
significant differences in levels of IFN-γ in comparison to all the
other treatment groups.
Animals treated with v50ΔB13RMγ show decreased
tissue necrosis, edema, and epithelial sloughing into
the nasal cavity
Histological analysis of nasal tissue was performed in order
to determine differences in pathology following treatment with
v50ΔB13RMγ. Staining for VACV antigen in a coronal section
Figure 5.  Measurement of IFN-γ in the serum following treatment.  Groups of 5 C57BL/6 mice were mock-infected or infected
IN with 106 pfu (~100 LD50s) of wt VACV. One day post infection mice were either mock-treated or treated with 107 pfu of v50ΔB13R
or v50ΔB13RMγ. After 24 hours, serum was harvested and an ELISA was performed to measure IFN-γ. The horizontal line
indicates the average and error bars indicate the standard error of the mean. Comparisons were done using the Mann-Whitney test.
One asterisk (*) represents p<0.008 in comparison to the wt/v50ΔB13RMγ group. Two asterisks (**) represents p<0.016 in
comparison to the wt/v50ΔB13RMγ group.
doi: 10.1371/journal.pone.0077879.g005
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of the nasal cavity showed that in a wt VACV infection followed
by mock treatment, virus replicated in the epithelial cell layer
early during infection by day 3. As infection progressed, VACV
replication moved into the underlying submucosal tissue and
epithelial sloughing, tissue necrosis, and edema were evident
(Figure 6A). By 8 dpi in mock-treated animals, the nasal cavity
was unilaterally blocked and replication had progressed in both
dorsal and lateral directions (Figure 6B). Additionally, in deeper
sections (> 2mm depth) infection progressed in a posterior
direction toward the olfactory bulbs (data not shown). In
animals treated with v50ΔB13RMγ, VACV staining was
observed at day 3 in the epithelial cell layer, however at days 5
and 8, a reduced progression of VACV staining into the
submucosal tissue was observed as well as reduced levels of
tissue necrosis and edema (Figure 6A). Photographs of the
entire nasal passages show that in v50ΔB13RMγ-treated
animals at 7 dpi VACV replication was evident along the airway
epithelium but did not progress dorsally or laterally as
compared to mock-treated animals (Figure 6B). In addition, in
animals treated with the parental virus, v50ΔB13R, replication
proceeded both dorsally and laterally in the tissue and stained
more intensely, likely due to the extra virus added upon
vaccination. Leukocyte influx into the nasal cavity was elevated
in animals treated with v50ΔB13RMγ at 2 dpi (1.4 x 105 cells)
as compared to infected, mock-treated animals (3.2 x 104 cells)
and to mock-infected, mock-treated mice (6 x 103 cells).
However, numbers of leukocytes in the nasal cavity between
the treated and untreated animals were similar by 4, 6 and 8
dpi (data not shown).
Efficacy of therapeutic administration of v50ΔB13RMγ
to animals infected with ECTV
ECTV infection which causes mousepox, has an LD50 of 90
pfu in C57BL/6 mice following IN infection, and models human
smallpox in terms of the level of respiratory susceptibility [48].
In order to determine if v50ΔB13RMγ can protect animals
against a lethal IN ECTV infection, C57BL/6 mice were infected
IN with 5 x 103 pfu of ECTV (55 LD50s) and treated by the foot
pad (FP) route one day post-infection with 3 x 107 pfu of
v50ΔB13RMγ or v50ΔB13R. As shown in Figure 7, both
v50ΔB13RMγ (P<0.0001, log-rank test) and v50ΔB13R
(P<0.005, log-rank test) immunizations provided significant
protection against a lethal ECTV IN infection with 83.3% and
50% survival, respectively, as compared to the mock-treated
control group, however the protection afforded by immunization
with v50ΔB13RMγ was significantly better than the control
v50ΔB13R (P<0.05, log-rank test).
Figure 6.  Histopathologic comparison and infection progression in the nasal cavity section.  Mice were infected IN with 106
pfu (~100 LD50s) of wt VACV and treated one day post-infection with 107 pfu of v50ΔB13RMγ. Mice were sacrificed at 7-8 days post-
infection. All representative sections were stained with polyclonal antibodies against VACV. S=septum, T=maxilloturbinate,
M=meatus (air passage), i=incisor. (A) Maxilloturbinate section, 2 mm depth, 100X magnification (B) Whole section, 5-6 mm depth.
10X magnification. Lines indicate 200 μm length.
doi: 10.1371/journal.pone.0077879.g006
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Discussion
There are currently anecdotal studies regarding the efficacy
of post-exposure vaccination protection of individuals when
administered up to 4 days post-exposure [22]. The present
work was intended to evaluate potential vaccine candidates for
prophylaxis after exposure to a pathogenic orthopoxvirus.
While other post-exposure prophylaxis studies have been done
using replication-deficient and replication-competent VACV
vaccine strains in order to protect against a lethal infection with
VACV-WR or ECTV [23][24][49], our study is the first one that
successfully uses a recombinant VACV expressing IFN-γ,
v50ΔB13RMγ, for post-exposure protection. Our results
suggest that IFN-γ is acting as a modulator of the immune
response rather than an antiviral.
Previous studies have demonstrated that VACV expressing
IFN-γ can be used as an adjuvant as well as an attenuating
agent for the production of live vaccines that are both safe and
have high efficacy [50][51]. Moreover, expression of IFN-γ has
also been used to influence the course of bacterial infection,
where VACV as a vector was more effective than fowlpox [52].
Other viruses such as bovine herpesvirus-1 (BHV-1) have also
been used to express IFN-γ and the stability of the BHV-1/IFN-
γ virus as well as its immunomodulating effects studied upon
primary infection and following reactivation of a latent infection
[53]. Moreover expression of human IFN-γ by a simian
immunodeficiency virus (SIVHyIFN) has shown reduced viral
loads in the blood of rhesus macaque monkeys that were
infected with this recombinant virus, even in the presence of a
progressive deletion of the IFN-γ gene. These results suggest
that the early immune system activation by SIVHyIFN was able to
confer protection against new emerging SIV viruses lacking full
expression of the lymphokine [54]. Expression of IFN-γ in
bacteria has also been studied. Administration of a
recombinant IFN-γ produced in E. coli at the time of a primary
immunization with vesicular stomatitis virus glycoprotein (VSV-
G) for example, enhanced secondary antibody responses even
at low doses [55]. The use of recombinant murine IFN-γ to
prevent lethal respiratory VACV infection has also been
Figure 7.  Protection of wt ECTV infected animals by post-exposure vaccination with v50ΔB13RMγ at one day post-
infection.  Groups of 30 C57BL/6 mice were infected intranasally with 5 x 103 pfu (~50 LD50s) of wt ECTV. Animals were treated by
FP route with saline (■), 3 x 107 pfu of v50ΔB13RMγ (▲) or v50ΔB13R (●) at one day post-infection. One group of animals was
mock infected and mock-treated (◊). The data were pooled from two independent experiments using group sizes of 10 and 20 mice.
P values (log-rank test) show the significance of difference with respect to ECTV/Mock. The boxed P value shows the significance
of the difference between v50ΔB13RMγ and v50ΔB13R.
doi: 10.1371/journal.pone.0077879.g007
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successful [44] although the challenge dose of VACV was
significantly lower than the ones used in this study.
IFN-γ is known to regulate the immune system by activating
macrophages and neutrophils, enhancing NK cell activity,
regulating B and T cell responses to antigens, stimulating
specific cytotoxic T cells, promoting chemokine expression, as
well as contributing to the protection against viral pathogenesis
[26][44][45][46][47]. Mice bearing a disrupted IFN-γ gene have
impaired production of macrophage antimicrobial products,
reduced major histocompatibility complex (MHC) class II
expression and are more vulnerable to infections against
pathogens such as Mycobacterium bovis [56] and Plasmodium
falciparum [57]. It has also been observed that during a VACV
infection IFN-γ inhibits VACV replication through the induction
of nitric oxide synthase (iNOS) in murine macrophages which
leads to the production of nitric oxide (NO) from the guanidine
nitrogen of L-arginine [58]. IFN-γ is the only known cytokine to
induce NOS in macrophages, production of NO in turn affects
DNA replication of VACV preventing virus particle formation
[58][59]. As noted in this study, although all animals infected
with wt VACV survived upon treatment with v50ΔB13RMγ,
VACV was found present in all the organs examined
suggesting that this virus is acting more as an immunoregulator
than as an antiviral. Thus, v50ΔB13RMγ could be indeed
orchestrating immune responses that could lead to less
morbidity and mortality in this animal VACV model.
Several parameters were studied in order to optimize post-
exposure protection in our animal model. IN infection was
chosen for challenge as the respiratory route is considered to
be the natural route of transmission for smallpox [60]. We
found that the route of treatment was important, and IN
treatment was the most effective in our VACV-WR model.
Survival rate of animals infected IN with wt VACV and treated
with v50ΔB13RMγ, especially into the same naris as the
challenge, provided complete protection while the use of other
routes of treatment reduced the survival rate to 40% (INON)
and 20% (IM and SCA) (Figure 3). Similarly, in a study by Staib
et al. (2006), mice infected IN with 5 x 104 pfu (1 LD50) VACV-
WR strain and then treated IM at 1, 2, 3 or 4 dpi with 108
infectious units of the modified VACV Ankara (MVA) died by
day 9 and had no effect compared with mock-vaccinated
animals. Mice infected IN with 106 pfu VACV-WR and treated
by scarification with 106 pfu VACV Elstree strain presented
similar results [24]. The fact that in our model treatment is more
effective when administered at the same site of the infection
could be explained in part by the low replication levels of
v50ΔB13RMγ in vivo (Figure 4C) [32]. This virus is attenuated
and required a high dose (1 x 107 pfu) for effective vaccination.
We also found that the effectiveness of IN vaccination was
dependent on expression of IFN-γ as treatment with the
parental virus v50ΔB13R, only provided 20% efficacy in this
model (data not shown). Moreover, although v50ΔB13RMγ
does not spread well in tissues, it replicates to low levels in the
nasal cavity of treated animals (Figure 4C), which could
contribute, to an increase in the effectiveness of the
prophylactic treatment. Additionally, the VACV-expressed IFN-
γ binding protein (IFN-γ BP) has a low affinity for murine IFN-γ
[61], making the availability of murine IFN-γ higher when used
for treatment of a VACV-WR infection. Finally, the need to treat
the same naris as the initial infection may, in a VACV model,
show a need for direct immunomodulation of the inflammatory
infiltrate which localizes at the primary site of infection. We
have observed that infection of a single naris results in a
unilateral region of viral replication and cellular infiltrate in the
sinus cavity (Figure 5B).
Treatment with a similar recombinant virus,
v50ΔB13RMIL-18, which expresses IL-18 (an IFN-γ inducing
factor), was partially successful in protecting mice from death
and the viral spread to tissues was similar to wt VACV (data
not shown). This partial protection could be due to the fact that
VACV expresses an IL-18 binding protein, which binds IL-18
tightly [62][63]. Altogether these results suggest that post-
exposure treatment in the VACV-WR model has more efficacy
when administered in the same site of infection and that the
expression of IFN-γ is more effective than treatment with
conventional vaccine strains.
Another parameter that was examined was time of post-
exposure treatment. We demonstrate that post-exposure
immunization with v50ΔB13RMγ is more effective in protecting
mice against a lethal infection with VACV-WR when
administered one day post-infection (Figure 2). Other studies
have proven that post-exposure protection against a challenge
dose of 1 to 3 LD50s is possible when treatment with MVA is
applied the same day of infection [23][24]. The action of IFN-γ
by itself has been proven to be effective against a challenge
dose of 8 LD50s when treatment was administered one day
before or the same day of infection. IFN-γ treatments started at
1, 2, and 3 dpi resulted in 90, 70, and 50% survival rates,
respectively [44]. In contrast, our results show the efficacy of
v50ΔB13RMγ for post-exposure vaccination prophylaxis
following a challenge dose of 100 LD50s of VACV-WR with 100,
40 and 20% survival when treatment was administered at 1, 2
or 3 dpi respectively (Figure 2).
Despite seeing less morbidity and no mortality in the treated
animals with v50ΔB13RMγ, we observed weight loss and viral
replication in the organs that we examined. Weight loss has
been correlated with fever and is a reliable method of
determining relative pathogenesis [64]. Our study shows a
continual weight loss in animals infected with wt VACV.
However, animals treated with v50ΔB13RMγ lost a maximum
of 25% weight and recovered rapidly (Figure 4) reaching a
weight comparable to uninfected animals by day 18 (data not
shown). While our data show that viral load and tissue
distribution were similar for both untreated and treated groups
up to 6 dpi, mice infected with wt VACV died by day 8 (Figures
4A and 4B). In our study, viral titers in most of the affected
organs from treated animals diminished after day 6 and by day
10 wt VACV was found only in the nasal cavity, brain, and
lungs (one animal with titers in all three tissues and one animal
with titers in nasal cavity and lungs only) (Figure 4B). Viral
replication of wt VACV in the nasal cavity, brain, lungs, ovary,
spleen and liver has been previously observed [23][31][65].
Immunohistochemistry results in our VACV model showed less
necrosis and edema blocking the air passage in all of the
animals that were treated with v50ΔB13RMγ as compared to
the mock-treated animals (Figure 5). These results correlate
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with a significantly lower viral load in the olfactory bulb of
v50ΔB13RMγ treated animals (7.16 x 106 pfu/g) at 6 dpi in
comparison with mock-treated animals (1.53 x 108 pfu/g)
P=0.0062, one way ANOVA, data not shown). However all
other tissues tested, including the nasal cavity, showed similar
viral titers in treated versus untreated animals, and this
suggests that the expression of IFN-γ is not acting as a direct
antiviral.
Upon treatment with v50ΔB13RMγ serum levels of IFN-γ
were elevated in comparison to untreated or v50ΔB13R-treated
animals. The higher levels of serum IFN-γ can be correlated
with the low but measurable titers of v50ΔB13RMγ in the nasal
cavity, brain, heart, and lungs of wt-infected mice and with the
survival of these mice. A previous study using this virus has
shown that infection with v50ΔB13RMγ alone results in
undetectable viral titers as compared to v50ΔB13R, yet
promotes potent antibody, T-helper and cytotoxic T cell
responses [32]. It appears that treatment with v50ΔB13RMγ
into the same naris following wt infection allows a low level of
v50ΔB13RMγ replication and may at the same time promote a
protective immune response. This has been observed during
coinfection with MVA viruses expressing the HIV env gene and
IFN-γ. In this study, the addition of MVA expressing IFN-γ upon
infection similarly resulted in elevated serum levels of IFN-γ
along with an increased CD8+ T cell response [66]. At the
same time, MVA expressing IFN-γ did not affect the levels of
viral gene expression in tissues, so the expression of IFN-γ
appeared to be primarily immunomodulatory in effect.
Because IN treatment with v50ΔB13RMγ was shown to
prevent death in mice infected with wt VACV, we performed an
experiment in order to determine the efficacy of post-exposure
protection in a heterologous mousepox model which has been
useful for testing both antivirals and vaccines and mimics
human smallpox due to its infection of the respiratory tract and
blood viral load [67][68]. Post-exposure vaccination also
mimics the human system since the vaccine would be given by
the intradermal route. We challenged A/Ncr and C57BL/6 mice
IN with a lethal dose of ECTV. Opposite to what we observed
in the VACV-WR model, IN treatment with v50ΔB13RMγ was
unable to prevent mortality in A/Ncr and C57BL/6 mice and all
animals died by day 10 (data not shown). The footpad route
was then chosen as the route of treatment as this mimics the
method that would be used for vaccination in humans. In our
study, survival was 83.3% when animals were treated 1 dpi
with v50ΔB13RMγ, and we observed a 50% survival when
vaccinating with the parental v50ΔB13R. Previous results have
demonstrated that post-exposure protection against ECTV was
dose and time dependent with similar protection of 83% at 1
dpi following ID vaccination with VACV Lister [23]. While VACV
Lister proved to be effective in protecting animals from a lower
dose challenge of ECTV (3-5 LD50s) in Paran's study,
v50ΔB13RMγ was able to protect mice infected with a higher
dose challenge of 55 LD50s. Both studies used ID prophylactic
vaccination and the treatment with either VACV-Lister or the
attenuated v50ΔB13R was sufficient to partially protect animals
after IN challenge with ECTV. Although v50ΔB13RMγ has
been shown to replicate poorly in tissues [32], its increased
effectiveness upon prophylactic vaccination is likely due to a
sufficient antigenic dose (3 x 107 pfu) along with expression of
IFN-γ.
Differences between the VACV and the ECTV model may be
due to the events following infection using different routes of
inoculation as well as disease progression. Such differences
have been previously reported in an ECTV infection model [23]
[69][70]. Moreover, failure to protect infected mice by IN
treatment could be attributed to the fact that the IFN-γ BP
expressed by ECTV has been shown to inhibit the biological
activity of murine IFN-γ [71][72][73]. Thus, any IFN-γ
synthesized in the nasal cavity would likely be inactivated by
ECTV's IFN-γ BP. Efficacy of the foot pad treatment could be
explained by v50ΔB13RMγ reaching a draining lymph node,
expressing IFN-γ to enhance the adaptive immune response,
which due to the extended incubation time of ECTV, had time
to mount an effective immune response against wt VACV. It
has been previously shown that strong antibody, CD4, and
CD8 responses are generated upon infection by v50ΔB13RMγ
in spite of the low replication levels in vivo [32]. While treatment
with the parental virus v50ΔB13R had low efficacy in the VACV
model, it had some effect in the ECTV model (Figure 6). This
suggests either that the deletion of the serpin homolog B13R
could be boosting the anti inflammatory response by allowing
the proteolytic activity of caspase-1, potentially increasing IL-18
activity and increased IFN-γ expression, or simply that
prophylactic vaccination with an adequate dose of VACV would
allow a sufficient inflammatory response for rescue [35].
Overall our results suggest that v50ΔB13RMγ may be
working as a stimulator and modulator of the immune response
rather than as an antiviral due to the similar viral titers
observed in tissues of untreated versus v50ΔB13RMγ-treated
wt VACV infected mice. IFN-γ is known to mediate several
immune responses including activation of macrophages and
neutrophils, enhancement of the NK cell activity, regulation of B
cell functions, stimulation of specific cytotoxic T cell immunity,
chemokine gene expression, increase in expression of MHC
class I and II proteins, leukocyte attraction to the site of
infection as well as contributing to the growth, maturation and
differentiation of many cell types [26][44][45][46][47]. While
v50ΔB13RMγ is a highly attenuated virus, it is still able to
induce humoral, T helper, and cell-mediated immune
responses[32]. We speculate that following infection with
VACV, v50ΔB13RMγ infects cells and initiates a rapid Th1
response, as indicated by the rapid influx of leukocytes at 2 dpi
in treated mice compared to controls. This rapid response
would have a "delay" effect on the infection giving the animal
time to mount a more robust immune response against VACV.
Further studies are necessary in order to determine the
immunological mechanisms involved in this process and which
cells are the key players.
This work demonstrates that expression of murine IFN-γ by a
recombinant VACV is able to confer a reduction in
pathogenesis and prevent mortality in mice infected with a
lethal dose of wt VACV as well as to reduce mortality in an
ECTV model. Our results highlight the importance of IFN-γ as a
modulator of the immune response for post-exposure
prophylaxis. Immunization with a recombinant virus expressing
IFN-γ is known to prevent viremia and death [44][46] as well as
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promote a potent immune response [32]. Thus, the use of
v50ΔB13RMγ could be an effective way to optimize post-
exposure prophylaxis against smallpox and other
orthopoxviruses infections. Moreover, together with ST-246,
CMX001, cidofovir and VIGIV, VACV expressing IFN-γ could
be utilized as another tool for post-exposure prophylaxis
treatment.
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